Urinary Catheterization, Hematuria, and Bladder Cancer

1. Urinary Catheterization

Overview

Types

• Short-term indwelling (Foley) catheter - common in acute hospital settings
• Clean Intermittent Catheterization (CIC) - preferred for long-term management (e.g., neurogenic bladder); evidence shows early initiation of CIC decreases UTI rates compared to prolonged indwelling catheter use
• Suprapubic catheter - placed through the abdominal wall, used when urethral access is contraindicated

Complications

• The most common complication of indwelling catheters
• Organisms form a biofilm on the catheter surface, protecting them from urine flow, host immunity, and antibiotics
• Short-term catheters (<30 days): usually single organisms - E. coli, Klebsiella, Pseudomonas, Enterobacter, staphylococci
• Long-term catheters (>30 days): usually polymicrobial - E. coli, Proteus mirabilis, Pseudomonas, Morganella morganii, Candida spp.
• Symptoms of CAUTI include fever, rigors, altered mental status, malaise, pelvic discomfort, acute hematuria, flank pain, and costovertebral angle tenderness
• Pyuria is universal in long-term catheterized patients and should NOT be used alone to diagnose symptomatic infection in the absence of clinical symptoms

• Remove or replace the catheter (replace if in place >14 days)
• Asymptomatic bacteriuria in short-term catheterized patients does NOT require antibiotics (unless pregnant or urologic procedure is pending)
• Empiric antibiotics for symptomatic infection; tailor based on culture results
• 7 days if prompt resolution; 10-14 days for delayed response
• Asymptomatic candiduria does not require treatment unless immunocompromised; if symptomatic, antifungal therapy for 14 days

• False passages in the urethra during insertion
• Hematuria from direct urethral or bladder irritation
• Pain or erosion at the urethral meatus
• Rarely, bladder perforation (sometimes accompanied by bowel perforation with chronic indwelling catheter)
• Nontotal deflation of the balloon during removal can cause urethral trauma

Campbell Walsh Wein Urology and Tintinalli's Emergency Medicine

2. Hematuria

Definition

• Gross hematuria: blood visible to the patient or physician
• Microscopic hematuria: ≥3 RBCs/hpf on urinalysis in adults; >5 RBCs/hpf on two weekly samples in children
• The urine dipstick alone is insufficient - it can be positive without RBCs present (pseudohematuria from myoglobin, certain foods/medications). A midstream clean-catch microscopy is required to confirm true hematuria

Clinical Significance

• Hematuria may signal a urologic cancer in up to 25% of patients
• The most common cause of gross hematuria in patients older than 50 years is bladder cancer
• The malignancy rate in screening studies for microhematuria is approximately 2.6%
• 61% of patients with hematuria have no significant pathology found after evaluation

Localization by Timing

• Initial stream hematuria - mild bleeding from prostatic or urethral source
• Total stream hematuria - upper tract or diffuse bladder source
• Terminal hematuria - bladder neck irritation, expressed at end of urination (e.g., bladder cancer, prostatitis)

Clot Morphology

• Vermiform (worm-shaped) clots - origin in the upper urinary tract (ureter/renal pelvis)
• Cuboid clots - formed within the bladder

Differential Diagnosis

Risk Factors Mandating Full Urologic Evaluation

• Age >50 years
• Smoking history
• Occupational exposure to aromatic amines, benzidine, rubber/dye industries
• Alkylating chemotherapy (cyclophosphamide)
• Analgesic abuse
• Chronic foreign body in urinary tract (catheter, stone)
• History of pelvic radiation

Evaluation

1. Urine cytology - detects cancer in only ~50% of high-grade bladder cancers
2. Cystoscopy - direct visual examination of the bladder; the most effective means to diagnose bladder cancer
3. CT urogram - evaluates kidneys and upper urinary tract
4. MR urogram - substitute in patients with poor renal function
5. Fluorescent in situ hybridization (FISH) - detects cancer-associated chromosomal changes in urine; useful for recurrence surveillance
6. Blue light cystoscopy / Narrow-band imaging cystoscopy - improve detection of small and flat (non-invasive) tumors; now used routinely in bladder cancer surveillance
7. Ureteroscopy or retrograde pyelography - when upper tract tumors are suspected with no bladder findings

Campbell Walsh Wein Urology, Harrison's Principles of Internal Medicine 22E, Textbook of Family Medicine 9e

3. Bladder Cancer

Epidemiology

• ~81,190 new diagnoses per year in the US
• Men have 3x the incidence of women
• Incidence in white men is 2x that of African American men
• Over 700,000 Americans live with bladder cancer
• Highly recurrent disease

Risk Factors

Histology

• Urothelial carcinoma (transitional cell carcinoma) - 90% of cases; best prognosis
• Squamous cell carcinoma - 5-10%; associated with chronic infection, calculi, catheter use, schistosomiasis
• Adenocarcinoma - 1-2%; primary or urachal origin
• Small cell/undifferentiated carcinoma - <1%; aggressive, usually presents with metastases

Histopathology Images

Figure A: Normal urothelium (125x)

Figure B: Moderately well differentiated papillary bladder cancer (60x)

Figure C: Carcinoma in situ (CIS) (200x)

Smith and Tanagho's General Urology, 19th Edition

Clinical Presentation

• Painless gross or microscopic hematuria - most common initial sign (present in virtually all cases)
• Irritative voiding symptoms: urgency, frequency, dysuria
• In women, hematuria due to malignancy can be mistaken for UTI or menstrual bleeding
• Flank pain if the tumor obstructs a ureteral orifice or if upper tract cancer is present
• Rarely: cachexia and widespread metastatic disease at presentation

Staging (TNM)

• 75-85% of cases are non-muscle-invasive (NMIBC) at diagnosis (stages Ta, Tis, T1)
• ~25% present with invasive or metastatic disease with no prior bladder cancer history
• Lymphovascular invasion even in node-negative disease is a poor prognostic factor

Staging Workup

1. TURBT (Transurethral Resection of Bladder Tumor) - includes examination under anesthesia (EUA), samples muscle wall to assess depth of invasion
2. CT scan (chest/abdomen/pelvis) - assess nodal and visceral metastasis
3. CT urography - evaluate upper urinary tracts
4. Bone scan - only if bone pain, known advanced disease, or elevated alkaline phosphatase
5. Restaging TURBT within 2-6 weeks if initial resection was incomplete or uncertain - especially important for Tis, Ta, T1, and T2 disease considered for bladder preservation

AUA Risk Stratification of NMIBC

Treatment

• Low-risk: TURBT alone + single immediate post-operative instillation of intravesical chemotherapy
• Intermediate-risk: TURBT + immediate intravesical chemotherapy + subsequent intravesical chemotherapy or BCG immunotherapy
• High-risk: TURBT + intravesical BCG immunotherapy; if BCG failure, radical cystectomy is warranted
• Recurrence rates after TURBT: 50-70% - hence adjuvant intravesical therapy is standard
• Intravesical chemotherapy (e.g., mitomycin C) reduces recurrence by 44-73% vs. TURBT alone
• BCG reduces recurrence by >50% vs. TURBT alone

• Radical cystectomy is the standard of care for T2-T4 resectable disease
• Neoadjuvant cisplatin-based chemotherapy before cystectomy improves survival
• Bladder preservation with trimodal therapy (maximal TURBT + radiation + concurrent chemotherapy) is an option in select patients
• For metastatic disease: cisplatin-based combination chemotherapy (e.g., gemcitabine + cisplatin)
• Checkpoint inhibitors (pembrolizumab, atezolizumab) are now used for cisplatin-ineligible patients and in the maintenance setting

Genetics and Molecular Biology

• FGFR3 mutations - common in low-grade papillary Ta tumors
• TP53 and RB1 alterations - associated with high-grade and muscle-invasive disease
• GWAS susceptibility loci identified: 8q24.21 (near MYC), 3q28 (TP63), 5p15.33 (hTERT), PSCA at 8q24.3, NAT2, UGT1A, GSTM1, and others
• Telomere dysfunction is implicated in chromosomal instability and cancer progression

Campbell Walsh Wein Urology, Schwartz's Principles of Surgery 11e, Smith & Tanagho's General Urology 19e, Harrison's Principles of Internal Medicine 22E

The Triangle: Catheter - Hematuria - Bladder Cancer

1. Catheter as cause of hematuria: Direct urethral or bladder irritation by a catheter causes hematuria. This is usually transient and mild but requires distinction from other causes, especially in at-risk patients.
2. Catheter-associated hematuria vs. cancer: When a catheterized patient develops hematuria, clinical context matters. Acute hematuria in a CAUTI setting has characteristic features (fever, altered mental status), whereas tumor-related hematuria is typically painless and may be intermittent. If hematuria persists after catheter removal and resolution of infection, full urologic evaluation (cystoscopy, CT urogram) is warranted.
3. Chronic catheter use as a carcinogen: Prolonged indwelling catheterization (especially in paraplegic patients) causes chronic mucosal irritation and inflammation, predisposing to squamous cell carcinoma of the bladder. These tumors are often nodular and already invasive at diagnosis.
4. Bladder cancer causing need for catheterization: Large bladder tumors obstructing the bladder outlet or causing massive hemorrhagic cystitis with clot retention may require catheterization - including three-way catheters for continuous bladder irrigation (CBI). Note that clots can obstruct an indwelling catheter.
5. Hematuria as the bridge: Hematuria is the unifying symptom - it is the cardinal presenting sign of bladder cancer AND a complication of catheterization AND a feature of CAUTI. Accurately characterizing hematuria in a catheterized patient requires careful clinical reasoning.

Recent Evidence (2024-2026)